AstraZeneca continues appeal against US court ruling over asthma drug
28th May 2013 07:05
AstraZeneca said it will continue to "vigorously" defend the intellectual property rights protecting its Pulmicort Respules medicine. The company is appealing against a US court ruling that the patent protecting Pulmicort from rival drugs in the US is invalid. The US Court of Appeal has issued a
Read moreMonday broker round-up UPDATE
29th Apr 2013 08:17
Afren: Liberum Capital shifts target price from 130p to 136p and maintains a hold recommendation. AngloAmerican: Nomura upgrades from reduce to neutral with a target price of 1700p. Antofagasta: Nomura cuts target price from 1250p to 1200p, while its neutral rating remains unchanged. Investec redu
Read moreMonday newspaper round-up: BP, AstraZeneca, Sainsbury's...
29th Apr 2013 06:48
The Telegraph writes that BP's giant underwater oil project offshore Angola has come in four billion dollars over budget after delays set it back a year. According to The Independent, unions are meeting with AstraZeneca in an attempt to convince the pharmaceuticals group to reverse plans to shut do
Read moreFriday tips round-up: Admiral, AstraZeneca
26th Apr 2013 08:41
With the motor market under a great deal of regulatory and political scrutiny, The Times' Tempus column has recommended investors to stay clear of Admiral following its 'unimpressive' trading statement on Thursday. The paper said that Admiral gave its critics plenty of ammunition yesterday, reveali
Read moreFriday broker round-up UPDATE
26th Apr 2013 07:24
Admiral Group: HB Markets initiates with a buy recommendation. AstraZeneca: Deutsche Bank takes target price from 3100p to 3160p and leaves its hold recommendation unchanged. Avon Rubber: Investec upgrades from hold to add with a target price of 420p. Betfair Group: Citigroup raises target price
Read moreLondon close: Markets underwhelmed by strong growth figures
25th Apr 2013 17:00
UK growth figures prompted a mixed reaction on stock markets on Thursday as stronger-than-expected activity in the first quarter quashed hopes that the Bank of England (BoE) would ramp up its quantitative easing programme in order to kick-start the economy. Nevertheless, data from the States lifted
Read moreFTSE 100 movers: Miners lead the risers
25th Apr 2013 15:23
Mining stocks rose on Thursday on the back of rising metal prices, led by Randgold Resources, Antofagasta, Vedanta, ENRC, and Polymetal. Heading the other way was consumer good group Unilever after it had to rely on robust growth from emerging markets as it grew marginally slower than expectations
Read moreLondon midday: Stocks fall as GDP data quashes stimulus hopes
25th Apr 2013 11:46
Better-than-expected growth figures from the UK underwhelmed stock markets on Thursday morning, tempering hopes that the Bank of England (BoE) would ease policy to boost the economy. Stocks have risen strongly over the past few days after a number of disappointing economic figures from the Eurozone
Read moreBroker tips: Vodafone, AstraZeneca, Admiral
25th Apr 2013 10:51
A potential offer by Verizon (VZ) for Vodafone's stake in their US wireless joint venture would have to increase substantially to please the British telecom group's shareholders, according to Jefferies. Jefferies said: "The glaring issue raised by last night's [Reuters] article is of course price.
Read moreBroker snap: Panmure says AstraZeneca up with events after strong run
25th Apr 2013 09:54
First-quarter results from AstraZeneca were broadly in line with forecasts with the stock is up with events after a good run of late, according to Panmure Gordon. Core earnings per share came in at 141 cents in the first three months of the year, ahead of the consensus forecast of 135 cents and in
Read moreLondon open: Stocks rise ahead of UK GDP
25th Apr 2013 08:28
Markets opened strongly on Thursday morning as strength in the mining sector lifted the FTSE 100 higher ahead of the release of UK growth data. British gross domestic product (GDP) is widely expected to have expanded by 0.1% in the first quarter, according to consensus estimates, rebounding after a
Read moreLoss of exclusivity on several brands hurts AstraZeneca in Q1
25th Apr 2013 07:11
Revenue contracted 12 per cent to 6.39bn dollar in the first quarter at FTSE 100-listed pharmaceuticals group AstraZeneca after losses of exclusivity for Seroquel IR and Atacand in many markets, and for Crestor in Canada. The group reported that growth for Symbicort, Brilinta, Iressa and the inclus
Read moreThursday preview: AstraZeneca and Unilever report
24th Apr 2013 14:48
AstraZeneca and Unilever will take centre stage Thursday when the FTSE 100 companies reveal their first quarter results. Drug giant AstraZeneca is expected to report an earnings per share of $1.41, compared to the group's consensus of $1.37, according to Panmure Research. "The stock has significa
Read moreMonday broker round-up UPDATE
22nd Apr 2013 07:20
Admiral Group: Deutsche Bank takes target price from 1140p to 1300p retaining a hold recommendation. African Barrick Gold: Deutsche Bank ups target price from 173p to 180p staying with its hold recommendation. Albemarle & Bond: Canaccord Genuity reduces target price from 280p to 146p and downgrade
Read moreWednesday broker round-up UPDATE
10th Apr 2013 08:57
African Barrick Gold: Westhouse Securities upgrades from sell to neutral with a target price of 195p. Deutsche Bank reduces target price from 340p to 230p keeping its hold rating. African Minerals: Deutsche Bank reduces target price from 620p to 594p and leaves its buy recommendation unaltered. An
Read more